Tempus AI is expanding its partnership with Verastem Oncology to develop a companion diagnostic (CDx) for the latter’s ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a rare type of ovarian ...

Tempus completed confirmatory testing in Verastem’s Phase 2 RAMP-201 clinical trial, which evaluated the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian ...

The partnership builds on the success of Verastem’s Phase 2 RAMP-201 clinical trial, which led to the U.S. Food and Drug Administration’s accelerated approval of a combination therapy for KRAS ...

The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...

Calling it a “historic first,” FDA chief Marty Makary ordered every review decision at the agency to start using a new ...

FDA grants accelerated approval to Verastem's Avmapki Fakzynja for KRAS-mutated ovarian cancer; company plans $75 million ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Verastem Oncology’s oral combination therapy ...

In April 2025, Verastem strengthened its balance sheet by raising gross proceeds of approximately $75 million in a private placement of 3.4 million shares of its common stock and 7.3 million pre ...